Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Three Immune-Related Prognostic mRNAs as Therapeutic Targets for Pancreatic Cancer
Cangang Zhang et al.
FRONTIERS IN MEDICINE (2021)
Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
Gang Meng et al.
BRITISH JOURNAL OF CANCER (2020)
Knockdown of interferon-induced transmembrane protein 1 inhibited proliferation, induced cell cycle arrest and apoptosis, and suppressed MAPK signaling pathway in pancreatic cancer cells
Lei Zhang et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2020)
Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
Shyambabu Chaurasiya et al.
CANCERS (2020)
Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxe1nu nude mice
Syed Umar Faruq Syed Najmuddin et al.
PEERJ (2020)
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
Bharat Burman et al.
CANCERS (2020)
Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma
Gang Meng et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer
Zahiah Mohamed Amin et al.
SCIENTIFIC REPORTS (2019)
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Volker Schirrmacher et al.
BIOMEDICINES (2019)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
ISG15 in antiviral immunity and beyond
Yi-Chieh Perng et al.
NATURE REVIEWS MICROBIOLOGY (2018)
Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model
Kseniya S. Yurchenko et al.
PLOS ONE (2018)
Designer Oncolytic Adenovirus: Coming of Age
Alexander T. Baker et al.
CANCERS (2018)
Viruses as nanomedicine for cancer
Narayanasamy Badrinath et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer
So Young Yoo et al.
ONCOTARGET (2016)
In Vitro Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells
Ahmed M. Al-Shammari et al.
BIOMEDICINES (2016)
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
Volker Schirrmacher
BIOMEDICINES (2016)
RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMY9
Zhikui Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Expressing foreign genes by Newcastle disease virus for cancer therapy
F. L. Bai et al.
MOLECULAR BIOLOGY (2015)
ISG15: A double edged sword in cancer
Shyamal D. Desai
ONCOIMMUNOLOGY (2015)
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Olga V. Matveeva et al.
MOLECULAR THERAPY-ONCOLYTICS (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Antiviral Activity of Human OASL Protein Is Mediated by Enhancing Signaling of the RIG-I RNA Sensor
Jianzhong Zhu et al.
IMMUNITY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The genesis and source of the H7N9 influenza viruses causing human infections in China
Tommy Tsan-Yuk Lam et al.
NATURE (2013)
IFITM Proteins Restrict Viral Membrane Hemifusion
Kun Li et al.
PLOS PATHOGENS (2013)
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
Eric Hastie et al.
JOURNAL OF GENERAL VIROLOGY (2012)
XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification
Bing Zou et al.
MOLECULAR CARCINOGENESIS (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
IRF7: activation, regulation, modification and function
S. Ning et al.
GENES AND IMMUNITY (2011)
Structural basis of RNA recognition and activation by innate immune receptor RIG-I
Fuguo Jiang et al.
NATURE (2011)
The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin
Itay Lazar et al.
JOURNAL OF VIROLOGY (2010)
Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma
Jennifer Altomonte et al.
MOLECULAR THERAPY (2010)
Structural basis of oligomerization in the stalk region of dynamin-like MxA
Song Gao et al.
NATURE (2010)
Identification of XAF1 as a novel cell cycle regulator through modulating G(2)/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer
Jide Wang et al.
CARCINOGENESIS (2009)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Steve H. Thorne et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus
Adam Vigil et al.
CANCER RESEARCH (2007)
Antiproliferative activity of the human IFN-α- inducible protein IFI44
L. C. Hallen et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2007)
Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages
Raphaelle Romieu-Mourez et al.
CANCER RESEARCH (2006)
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J. H. Kim et al.
MOLECULAR THERAPY (2006)
Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence
Christoph Fiola et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity
DM Shayakhmetov et al.
JOURNAL OF VIROLOGY (2005)
Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes
G Kochs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
N Habib et al.
CANCER GENE THERAPY (2002)
Share Paper
